Navigation Links
TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
Date:5/14/2013

TAIPEI, Taiwan, May 14, 2013 /PRNewswire/ -- TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg from the United States Food and Drug Administration (U.S. FDA). Guanfacine Hydrochloride Extended-Release Tablet is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

"We are pleased to receive the tentative approval from U.S. FDA for our Guanfacine Hydrochloride product," said Dr. Calvin C. Chen , President of TWi Pharmaceuticals. "TWi had already reached a settlement agreement with the branded product manufacturer and intends to begin shipping its Guanfacine Hydrochloride product upon receiving the final approval from U.S. FDA."

According to IMS Health, a market research firm, the total annual sales of the branded product, Intuniv®, marketed by Shire US Inc., in U.S. were approximately $448 million in 2012.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact:

Michael L. Huang
Head of Investor Relations
Tel: +886-2-2657-3350
Email: michael.huang@twipharma.com


'/>"/>
SOURCE TWi Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013
2. Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events
3. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
4. Arbor Pharmaceuticals Announces FDA Approval of First NDA
5. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
6. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
7. Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
8. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
9. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
10. Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
11. The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
(Date:5/22/2017)... 2017  Lilac Corp, the company that sells ... of a new website . The website ... clinical study that showed surprising clearance of the ... individuals suffering from HPV warts, precancerous, or cancerous ... no other treatments that clear the virus. Specifically, ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... David B. Sosin, a founding partner at ... over the post of 2nd Vice President for the Illinois State Bar Association , ... the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in that ...
(Date:6/28/2017)... , ... June 28, 2017 , ... American Farmer proudly ... episode of the award winning television series, scheduled to broadcast fourth quarter 2017. American ... originated as a regional supplier of garden pea seed. As demand grew, the small ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a ... access to insurance assistance and financial planning services, is announcing the commencement of ... in the region facing financial crisis. , Matthew 25: Ministries (M25M) is an ...
(Date:6/28/2017)... Cincinnati, OH (PRWEB) , ... June 28, 2017 ... ... and financial consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is ... help provide temporary lodgings for families with children receiving treatment in nearby hospitals. ...
Breaking Medicine News(10 mins):